BRITAIN'S Medicines and Healthcare products Regulatory Agency (MHRA) has announced a new regulatory framework for Point of Care (POC) manufacturing of innovative medicines.
The UK would be the first country to introduce such guidance, which means new medicines with extremely short shelf lives, as well as highly personalised drugs, can more easily be made in or near a hospital setting or ambulance.
The framework aims to minimise regulatory barriers to innovative manufacturing while ensuring safety, quality and effectiveness.
The above article was sent to subscribers in Pharmacy Daily's issue from 06 Feb 23
To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 06 Feb 23
